BAM
SLDB icon

Belpointe Asset Management’s Solid Biosciences SLDB Stock Holding History

Belpointe Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,367
Closed -$7.35K – 3845
2022
Q4 		$7.35K Buy
+1,367
New +$8.96K ﹤0.01% 2764

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Belpointe Asset Management's SLDB Position: Q1 2023 in Review

Belpointe Asset Management sold out of Solid Biosciences (SLDB) in Q1 2023, closing a stake of 1,367 shares — an estimated $7.35K sold.

Belpointe Asset Management first reported a position in SLDB in Q4 2022 and held it in 1 quarter. The position peaked at $7.35K in Q4 2022. 39 funds tracked by Wall St. Rank hold SLDB as of Q1 2023.

  • Belpointe Asset Management reported no remaining Solid Biosciences position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,367 Solid Biosciences shares in Q1 2023, an estimated $7.35K.
  • Belpointe Asset Management first reported a position in Solid Biosciences in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Solid Biosciences position peaked at $7.35K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.